Enanta Pharmaceuticals (ENTA) Deferred Taxes (2014 - 2020)

Enanta Pharmaceuticals has reported Deferred Taxes for 7 years, with the latest figure at $15.0 million in Q3 2020.

• For the quarter ending Q3 2020, Deferred Taxes rose 1363.63% year-over-year to $15.0 million; the trailing twelve-month figure through Sep 2020 stood at $10.6 million (up 438.05% YoY), and the FY2021 full-year result was $345000.0, down 96.75% from the prior year.
• Deferred Taxes for Q3 2020 stood at $15.0 million, up from -$3.1 million in the prior quarter.
• The five-year high for Deferred Taxes was $15.0 million in Q3 2020, with the low at -$3.8 million in Q2 2017.
• Historically, Deferred Taxes has averaged $263052.6 across 5 years, with a median of -$918000.0 in 2018.
• Annual changes were most pronounced in 2016 — Deferred Taxes sank 5816.67% — and 2020, when it soared 1363.63%.
• Enanta Pharmaceuticals' Deferred Taxes stood at -$1.9 million in 2016, then surged by 239.37% to $2.7 million in 2017, then plunged by 134.49% to -$918000.0 in 2018, then surged by 171.57% to $657000.0 in 2019, then soared by 2179.15% to $15.0 million in 2020.
• The last three Deferred Taxes figures came in at $15.0 million (Q3 2020), -$3.1 million (Q2 2020), and -$1.9 million (Q1 2020), per Business Quant data.